Regent Biosciences

Regent Biosciences is a biotechnology company based in the United Kingdom that focuses on the discovery and development of small molecule drugs targeting RNA-binding proteins (RBPs). The company's research is centered on the role of RBPs in post-transcriptional gene regulation and their involvement in the pathogenesis of cancer and inflammatory diseases. By utilizing a proprietary screening platform, Regent Biosciences identifies compounds capable of modulating RBP-RNA interactions, aiming to address targets that have traditionally been difficult to reach with conventional therapies. The company is currently in the pre-clinical stage, working to validate its lead candidates for oncology and other high-unmet-need indications. Through its innovative approach to the RBP-RNA interactome, Regent Biosciences seeks to establish a new paradigm in precision medicine.